8-K: TransCode Therapeutics Addresses Convertible Note Default Risk

TransCode Therapeutics made a prepayment to avoid default on convertible notes tied to its stock price, while continuing its equity purchase agreement with Yorkville.

Summary

• TransCode Therapeutics entered into a waiver agreement with YA II PN, Ltd. (Yorkville) on October 1, 2026, to address potential default on convertible notes.
• The company made a prepayment of $840,975, which included $759,000 in principal, a $75,900 premium, and $6,075 in accrued interest.
• This prepayment was made to avoid an 'Amortization Event' triggered by the common stock's daily VWAP falling below $1.72 for five trading days within a seven-day period.
• The company experienced this condition for 10 out of 14 trading days between September 11, 2026, and September 30, 2026.
• Yorkville waived any Amortization Event that occurred up to September 30, 2026, and any that might occur through October 31, 2026, in exchange for the prepayment.
• Following the prepayment, approximately $4.1 million in principal remains outstanding under the convertible notes.
• The Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing the company to sell up to $14 million of common stock, remains in effect.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the company's financial strain and the terms of the equity purchase agreement, indicating potential dilution and ongoing funding challenges.

Positives

• The company successfully negotiated a waiver with Yorkville, preventing an immediate default on its convertible notes.
• Yorkville agreed to waive potential amortization events through October 31, 2026, providing a temporary reprieve.
• The SEPA with Yorkville remains active, offering a potential source of future capital up to $14 million.

Negatives

• The company's common stock price has been trading below the $1.72 floor price for convertible notes, indicating significant market pressure.
• A substantial prepayment of $840,975 was required to avoid default, impacting available cash.
• Approximately $4.1 million in convertible note principal remains outstanding, posing a continued financial obligation.
• The terms of the convertible notes and SEPA suggest potential for significant future dilution if the stock price does not recover.

Risks

• Continued trading of the common stock below the $1.72 floor price could trigger future Amortization Events and further payment obligations.
• The outstanding $4.1 million in convertible notes represents a significant financial liability that needs to be managed.
• The Standby Equity Purchase Agreement allows for the sale of up to $14 million in common stock, which could lead to substantial dilution for existing shareholders.
• The company's reliance on Yorkville for funding through the SEPA highlights potential ongoing financial vulnerability.

Future Outlook

The company continues to operate under a Standby Equity Purchase Agreement with Yorkville, allowing for potential future capital raises up to $14 million. However, the ongoing pressure on the stock price and the remaining convertible note balance present continued financial challenges.

Management Comments

• The company has taken steps to manage its financial obligations by entering into a waiver and making a prepayment to avoid default on its convertible notes.
• The agreement with Yorkville provides flexibility while the company continues its strategic objectives.

Industry Context

StockSavvy.ai notes that biotech companies, particularly those in clinical development stages like TransCode Therapeutics, often face significant funding challenges. The reliance on equity purchase agreements and convertible notes is common but can lead to substantial dilution and financial strain if key development milestones are not met or if market conditions are unfavorable.

Related Party Transactions

• The filing details transactions between TransCode Therapeutics and YA II PN, Ltd. (Yorkville), including a Standby Equity Purchase Agreement and convertible promissory notes.

Stakeholder Impact

• Shareholders may experience significant dilution if the company utilizes the full $14 million available under the SEPA.
• Creditors and noteholders face potential risks if the company's financial situation deteriorates further, impacting repayment of the remaining $4.1 million in convertible notes.

Next Steps

• Continue to monitor the company's stock price performance relative to the $1.72 floor price.
• Evaluate the company's ability to manage the remaining $4.1 million in convertible note principal.
• Assess the potential impact of future equity sales under the SEPA on shareholder dilution.

Key Dates

Recommendation

The company has avoided immediate default, but the underlying financial pressures, including stock price weakness and ongoing financing needs, warrant a cautious 'hold' rating. Further clarity on clinical progress and a sustainable financing strategy are needed for a more positive outlook.

Keywords

Convertible Notes, Equity Purchase Agreement, Default Waiver, Stock Price, Financing, Capital Raise, Dilution, VWAP